Multi‐Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial
Primary resultResult — go to the resultMean decrease in MRI-GFR 3.03 mL/min/1.73 m²Authors' conclusion
Multiparametric MRI can non-invasively demonstrate local renal impacts of empagliflozin beyond that of traditional markers of renal function, including decreased GFR and medullary hypoxia.
Study context
- Population
- Adults with T2DM with eGFR ≥ 45 mL/min/1.73 m² and any degree of albuminuria (CKD KDIGO G1, 2 or GF3a, A1-A3)12 completed
- Comparison
- Empagliflozin vs sitagliptin
- Primary endpoint
- Effect on MRI-derived GFR (Brochner-Mortensen corrected) and renal vascular resistance (RVR) by multiparametric MRI
- Follow-up
- 12 weeks
Methodological detailspilot, prospective, open-label, crossover, active comparator
- Pilot
- Prospective
- Open-label
- Crossover
- Active comparator
Primary result
As reported in the abstract
Mean decrease in MRI-GFR
3.03 mL/min/1.73 m²
P < 0.05
Further findings
| Outcome | Estimate | P value |
|---|---|---|
| Renal blood flow (RBF) · 12 weeks | mean decrease in RBF 41.24 mL/min | P < 0.05 |
| Medullary hypoxia (R2*) · 12 weeks | increase in medullary R2* 1.81 s-1 | P < 0.05 |
Corticomedullary microstructure, eGFR and albuminuria
- No statistically significant changes to corticomedullary microstructure, eGFR or albuminuria with empagliflozin
Original publication
Multi‐Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial. Diabetes Obes Metab. Published 4 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →